An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

The is a double-blind, randomized phase 3 study of 90Y-clivatuzumab tetraxetan with low-dose gemcitabine, versus placebo and low-dose gemcitabine in metastatic pancreatic cancer patients who have progressed on at least 2 prior therapies for metastatic cancer (1 of which was a gemcitabine-containing regimen).

开始日期2013-12-01

申办/合作机构

Gilead Sciences, Inc.

NCT01510561

/ Withdrawn临床1期

A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies.

90Y-hPAM4 is administered weekly for 3 weeks combined with 4 weekly doses of gemcitabine to assess. This is a dose escalation study of 90Y-hPAM4 to assess which dose is safe and effective as 3rd line treatment for patients with metastatic pancreatic cancer. Patients are then followed weekly for 12 weeks and afterwards for up to 1 year.

开始日期2012-03-01

申办/合作机构

Gilead Sciences, Inc.

NCT00603863

/ Completed临床1/2期

A Phase Ib/II Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Patients With Previously Untreated Advanced Pancreatic Cancer.

This is a study to test whether different doses of 90Y-hPAM4 are safe to give in combination with gemcitabine in patients with previously untreated pancreatic cancer.

开始日期2008-01-01

申办/合作机构

Gilead Sciences, Inc.

100 项与 90Y Clivatuzumab Tetraxetan 相关的临床结果

登录后查看更多信息

100 项与 90Y Clivatuzumab Tetraxetan 相关的转化医学

登录后查看更多信息

100 项与 90Y Clivatuzumab Tetraxetan 相关的专利（医药）

登录后查看更多信息

项与 90Y Clivatuzumab Tetraxetan 相关的文献（医药）

2015-09-01·European journal of cancer (Oxford, England : 1990)1区 · 医学

90 Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies

1区 · 医学

Article

作者: O'Neil, Bert H ; Wegener, William A ; Mitchel, Edith P ; Horne, Heather ; Richards, Donald A ; Pandit-Taskar, Neeta ; Sharkey, Robert M ; Gribbin, Thomas E ; Von Hoff, Daniel D ; Ocean, Allyson J ; Braiteh, Fadi S ; O'Reilly, Eileen M ; Frank, Richard C ; Guarino, Michael J ; Cohen, Steven J ; Lowery, Maeve A ; Ramanathan, Ramesh K ; Lee, Fa-Chyi ; Dragovich, Tomislav ; Manzone, Timothy C ; Conkling, Paul R ; Intenzo, Charles M ; Bridges, Benjamin B ; Picozzi, Vincent J ; Starodub, Alexander N ; Lee, Marie ; Bahary, Nathan ; Goldsmith, Stanley J ; Sheikh, Arif ; Goldenberg, David M ; Korn, Ronald L

BACKGROUND:

For patients with metastatic pancreatic adenocarcinoma, there are no approved or established treatments beyond the 2nd line. A Phase Ib study of fractionated radioimmunotherapy was undertaken in this setting, administering (90)Y-clivatuzumab tetraxetan (yttrium-90-radiolabelled humanised antibody targeting pancreatic adenocarcinoma mucin) with or without low radiosensitising doses of gemcitabine.

METHODS:

Fifty-eight patients with three (2-7) median prior treatments were treated on Arm A (N=29, (90)Y-clivatuzumab tetraxetan, weekly 6.5 mCi/m(2)doses×3, plus gemcitabine, weekly 200 mg/m(2) doses×4 starting 1 week earlier) or Arm B (N=29, (90)Y-clivatuzumab tetraxetan alone, weekly 6.5 mCi/m(2)doses×3), repeating cycles after 4-week delays. Safety was the primary endpoint; efficacy was also evaluated.

RESULTS:

Cytopaenias (predominantly transient thrombocytopenia) were the only significant toxicities. Fifty-three patients (27 Arm A, 26 Arm B, 91% overall) completed ⩾1 full treatment cycles, with 23 (12 Arm A, 11 Arm B; 40%) receiving multiple cycles, including seven (6 Arm A, 1 Arm B; 12%) given 3-9 cycles. Two patients in Arm A had partial responses by RECIST criteria. Kaplan-Meier overall survival (OS) appeared improved in Arm A versus B (hazard ratio [HR] 0.55, 95% CI: 0.29-0.86; P=0.017, log-rank) and the median OS for Arm A versus Arm B increased to 7.9 versus 3.4 months with multiple cycles (HR 0.32, P=0.004), including three patients in Arm A surviving >1 year.

CONCLUSIONS:

Clinical studies of (90)Y-clivatuzumab tetraxetan combined with low-dose gemcitabine appear feasible in metastatic pancreatic cancer patients beyond 2nd line and a Phase III trial of this combination is now underway in this setting.

2015-01-02·mAbs2区 · 医学

Antibodies to watch in 2015

2区 · 医学

Review

作者: Janice M Reichert

The commercial pipeline of recombinant antibody therapeutics is robust and dynamic. As of early December 2014, a total of 6 such products (vedolizumab, siltuximab, ramucirumab, pembrolizumab, nivolumab, blinatumomab) were granted first marketing approvals in 2014. As discussed in this perspective on antibodies in late-stage development, the outlook for additional approvals, potentially still in 2014 and certainly in 2015, is excellent as marketing applications for 7 antibody therapeutics (secukinumab, evolocumab, mepolizumab, dinutuximab, nivolumab, blinatumomab, necitumumab) are undergoing a first regulatory review in the EU or US. Of the 39 novel mAbs currently in Phase 3 studies, a marketing application for one (alirocumab) may be submitted in late 2014, and marketing application submissions for at least 4 (reslizumab, ixekizumab, ocrelizumab, obiltoxaximab) are expected in 2015. Other 'antibodies to watch' are those in Phase 3 studies with estimated primary completion dates in late 2014 or 2015, which includes 13 for non-cancer indications (brodalumab, bimagrumab, bococizumab, MABp1, gevokizumab, dupilumab, sirukumab, sarilumab, tildrakizumab, guselkumab, epratuzumab, combination of actoxumab + bezlotoxumab, romosozumab) and 2 (racotumomab and clivatuzumab tetraxetan) undergoing evaluation as treatments for cancer. In addition to the novel antibody therapeutics mentioned, biosimilar infliximab and biosimilar trastuzumab are 'antibodies to watch' in 2015 because of their potential for entry into the US market and regulatory review, respectively.

2014-07-01·mAbs

Antibodies to watch in 2014

作者: Reichert, Janice M

The commercial pipeline of monoclonal antibodies is highly dynamic, with a multitude of transitions occurring during the year as product candidates advance through the clinical phases and onto the market. The data presented here add to that provided in the extensive "Antibodies to watch in 2014" report published in the January/February 2014 issue of mAbs. Recent phase transition data suggest that 2014 may be a banner year for first approvals of antibody therapeutics. As of May 2014, three products, ramucirumab (Cyramza®), siltuximab (Sylvant®) and vedolizumab (Entyvio™), had been granted first approvals in the United States, and four additional antibody therapeutics (secukinumab, dinutuximab, nivolumab, pembrolizumab) are undergoing regulatory review in either the US or the European Union. Other notable events include the start of first Phase 3 studies for seven antibody therapeutics (dupilumab, SA237, etrolizumab, MPDL3280A, bavituximab, clivatuzumab tetraxetan, blinatumomab). Relevant data for these product candidates are summarized, and metrics for antibody therapeutics development are discussed.

项与 90Y Clivatuzumab Tetraxetan 相关的新闻（医药）

2026-10-02

·肽读

600.MUC1：癌症圈备受追捧的靶点，多款新药正在路上

提到癌症靶点，大家听得最多的是 PD‑1、HER2。但有一个靶点，在多种实体瘤里高表达，抗体、ADC、CAR‑T 多条技术路线齐头并进，它就是MUC1。很多人可能第一次听说 MUC1，它其实是人体细胞表面的一种糖蛋白。正常情况下身体就会合成它，可一旦细胞发生癌变，这个蛋白就会发生巨大改变，摇身变成肿瘤的 “帮凶”，也成了新药研发人员眼里的香饽饽。 MUC1 基因本身十分复杂，会发生多种可变剪接，生成不一样的转录本，也就是 MUC1/A、MUC1/B、MUC1/C 等多种变体。不同的变体，会直接影响蛋白的结构，进一步改变肿瘤细胞的生物学行为。完整的 MUC1 蛋白会分成两大核心部分：MUC1‑N 的 N 端胞外结构域，还有 MUC1‑C 的 C 端跨膜胞内结构域。胞外段存在大量串联重复序列，上面布满糖基化修饰；跨膜段牢牢锚定在细胞膜上，胞内片段则可以向细胞内部传递信号。癌变之后，MUC1‑C 还会脱离细胞膜，进入细胞质，甚至跑到细胞核当中。它可以招募各类转录因子，启动和肿瘤增殖、存活相关的基因，同时还能和 EGFR 等多条肿瘤信号通路互相配合，助力癌细胞存活、增殖。简单讲，这个蛋白不止待在细胞表面，还会钻进细胞内部，从根源上 “驱动肿瘤生长”。正常上皮细胞和癌细胞上的 MUC1，最大区别就在于糖基化。正常细胞上的 MUC1 糖基化完整，糖链长而饱满；但癌细胞里的 MUC1 会出现糖基化不足。糖链变短，原本被糖链盖住的蛋白肽段就暴露出来，这也是肿瘤特异性的关键特征。这也是药物能够区分癌细胞和正常细胞的重要基础。这种糖基化的差异，并不是简单的糖多少的区别。正常细胞会逐步把糖链延长；肿瘤细胞中糖链合成早早终止，出现 Tn 抗原、Sialyl Tn 抗原这类肿瘤特异性糖修饰。药物研发很多就是瞄准这些肿瘤特有的糖‑蛋白复合位点，实现精准打击癌细胞。从临床组织样本染色结果也能直观看到，在肿瘤组织里面，MUC1 有着明显的阳性信号，而正常组织表达水平很低。多癌种统计数据显示，MUC1 在乳腺癌、胰腺癌、肺癌、子宫内膜癌等众多恶性肿瘤中高频阳性。拿胰腺癌来说，从正常胰腺上皮，到 PanIN 癌前病变，再一步步向胰腺癌进展，MUC1 的表达水平会逐步升高。也就是说，在癌变早期阶段，MUC1 就已经开始上调，具备早期识别以及治疗靶点的双重价值。既然靶点价值明确，全球药企已经围绕 MUC1 铺开多条技术管线，单克隆抗体、ADC、放射性偶联药物 PDC、CAR‑T 细胞疗法全部都有布局。单克隆抗体方向，gatipotuzumab、BrevaRex 等候选药物已经推进到 Ⅰ/Ⅱ 期临床，面向实体瘤、多发性骨髓瘤开展研究。放射性药物（PDC）Yttrium Y 90 clivatuzumab tetraxetan 更是走到了 Ⅲ 期临床，针对胰腺癌开展探索。这款药物，把靶向 MUC1 的抗体和钇‑90 放射性同位素偶联，抗体找到肿瘤细胞之后，依靠同位素释放射线杀伤癌细胞。 ADC 赛道同样热闹。默克的 M‑1231、杭州 DAC 生物的 DXC‑005 均处于 Ⅰ 期临床，覆盖非小细胞肺癌、食管癌、结直肠癌、胰腺癌等难治癌种。部分双靶点 ADC，同时识别 MUC1 与 EGFR，再搭载微管抑制剂毒素，以此提升抗肿瘤效果。 TCGA 数据库的肿瘤样本分析还发现，在多种肿瘤中 MUC1 和 HER3 表达存在正相关，也给双靶点药物开发提供了理论依据。细胞治疗 CAR‑T 也没有落下。Mayo Clinic、Poseida、Kite 等机构企业的多款 MUC1 靶向 CAR‑T，已经进入 Ⅰ 期临床，覆盖多发性骨髓瘤和各类实体瘤。但也要客观看待：MUC1 靶点依旧存在不少挑战。它在部分正常上皮细胞有基础表达，如何避免误伤正常组织；肿瘤糖基化高度异质性，不同患者肿瘤的 MUC1 糖修饰并不完全一样，都是研发路上绕不开的难题。目前全部候选药物都还处在临床阶段，还没有药物正式获批上市，距离真正惠及患者还有一段路要走。不过这么多技术路线同时发力，也足以证明行业对这个靶点的期待。

2026-06-09

·上海丰能数字健康技术研究院

【文献解读075】放射性核素靶向策略在胰腺癌诊疗中的研究进展

——基于《药学进展》2025年综述的深度解读引言：临床痛点与破局之匙胰腺癌，素有“癌王”之称，是恶性程度最高的消化道肿瘤之一。其临床挑战严峻：位置隐蔽，早期无明显症状，导致80%-90%的患者确诊时已属晚期，失去手术机会。5年生存率仅约13%，且对传统放化疗及免疫治疗的反应不佳。诊断层面，常规影像学（如CT、MRI）在区分肿瘤与炎症/纤维化、检测微转移灶方面存在局限；治疗层面，如何实现精准打击并降低对正常组织的损伤是核心难题。2025年9月，《药学进展》期刊发表了一篇题为《放射性核素靶向策略在胰腺癌诊疗中的研究进展》的综述（作者：徐珊珊、李晓阳、洪浩、何健等），系统梳理了核医学如何通过整合功能成像与分子靶向治疗，为突破这些困局提供新思路。本文将基于该综述，结合领域内关键数据与前沿进展，进行深度剖析。一、临床常规与局限：18F-FDG PET/CT的现状1.1 基于“瓦尔堡效应”的经典应用 18F-FDG PET/CT是目前肿瘤显像中最常用的放射性药物之一。其原理基于癌细胞异常活跃的糖代谢（瓦尔堡效应）。超过90%的胰腺导管腺癌（PDAC）因KRAS突变，导致葡萄糖转运体（GLUT1）和己糖激酶Ⅱ过表达，使得肿瘤对FDG的摄取显著高于正常胰腺组织。该技术能提供全身性的分子代谢信息，在以下方面具有重要价值：1）辅助初诊时CT/MRI难以确诊的病灶；2）评估远处转移；3）监测治疗反应及鉴别复发与纤维化。1.2 不可忽视的临床局限然而，18F-FDG PET/CT的特异性仅为65%左右。其主要局限在于无法有效区分PDAC与局灶性慢性胰腺炎，导致假阳性风险。此外，患者的高血糖状态也会显著影响检查的准确性。这些局限性催生了对新型、高特异性放射性示踪剂的迫切需求。二、靶向肿瘤抗原：直击癌细胞的“精准导弹” 近年来，针对肿瘤细胞表面特异性抗原的放射性核素药物研发进展迅速。这些“精准导弹”不仅用于诊断，更在治疗上展现出潜力。下表汇总了文献中提及的主要靶向肿瘤抗原的探针及其研究现状。靶点代表性放射性示踪剂主要进展与临床阶段主要挑战/备注 MUC1 64Cu-DOTA-C595 (诊断), 177Lu/213Bi-C595 (治疗) 90Y-放射性标记抗体联合小剂量化疗的临床研究显示对部分转移性患者可行。研究仍处初级阶段，需优化示踪剂以改善预后。间皮素 64Cu/89Zr/111In-抗MSLN抗体, α核素标记物多种核素标记的抗体在临床前及早期临床中显示优异显像；α核素治疗潜力良好。存在肝生理性摄取，可能干扰腹膜转移评估。需开发小型化抗体或预靶向策略。 PSMA 68Ga/18F-PSMA 68Ga-PSMA在胰腺病变中阳性预测率高于FDG，为PSMA阳性患者带来治疗新希望。临床研究多为单中心、小样本。需更大规模试验验证。 PD-1/PD-L1 64Cu/68Ga/89Zr-抗PD-1/PD-L1抗体在其他癌种中展现良好反应；是评估免疫疗法的重要工具。在胰腺癌中单独使用免疫疗法效果不佳，需开发联合策略的示踪剂。大多研究仍处临床前阶段。 KRAS 131I-ARS-1620 (靶向G12C突变) 在体外和体内试验中能够直接成像并筛选KRAS G12C突变体。 KRAS是胞内蛋白，传统核素载体难以有效结合及递送。需研发穿透性更强的新型药物。笔者认为，靶向肿瘤抗原的策略虽然前景广阔，但其核心挑战在于如何平衡靶点的肿瘤特异性与生理分布、如何克服肿瘤致密间质屏障对药物递送的阻碍。例如，虽然CA19-9是临床最常用的血清标志物，但作为核素靶点，其敏感性和特异性不足，且血液中高水平的抗原会形成“血池”背景，显著降低肿瘤/本底比值。未来的探针设计必须向小型化、高亲和力、药代动力学优化的方向发展。三、靶向肿瘤间质：攻破“纤维化堡垒”的新路径 PDAC的另一显著特征是其富含纤维结缔组织和炎症反应的致密间质，这构成了抵抗治疗的“堡垒”。靶向间质成分已成为创新的诊疗策略。3.1 成纤维细胞活化蛋白：诊断的“明星靶点” 成纤维细胞活化蛋白（FAP）在超过90%的PDAC相关成纤维细胞（CAF）中高表达，而在正常组织中几乎不表达。68Ga-FAPI-04 PET/CT在临床应用中展现出优异性能。关键数据显示，与18F-FDG相比，68Ga-FAPI-04在检测原发肿瘤、淋巴结及远处转移方面具有更高的敏感性和图像对比度，在临床分期上优势明显。尽管其治疗应用（如90Y-FAPI-04）报道尚少，但无疑是当前胰腺癌诊疗一体化研究中的热点。3.2 整合素αvβ6与纤维连接蛋白：临床前潜力初显整合素αvβ6在PDAC中的阳性率超过95%。68Ga标记的靶向肽和177Lu-DOTA-胱氨酸结肽在临床前模型中显示出高亲和力和特异性，证明了其在成像与治疗中的双重潜力。靶向纤维连接蛋白（FN）剪接区域的纳米体64Cu-NJB2，则能在小鼠模型中检测到早期胰腺上皮内瘤变，为极早期诊断带来了曙光。然而，这些探针的临床转化仍需大型、确证性的Ⅲ期临床试验数据支持。四、核心要点与未来展望诊疗一体化是核心方向：放射性核素靶向策略的核心价值在于将诊断（Diagnostics）与治疗（Therapy）无缝整合，实现真正的精准医疗。多种探针（如靶向MSLN、FAP的探针）已初步展现出“一药两用”的潜力。靶点选择决定应用场景：FAP、整合素αvβ6等间质靶点因其穿透性强，在早期诊断和分期中可能更具优势；而MUC1、MSLN等肿瘤细胞抗原则可能更适合作为治疗载体的靶向选择。临床转化仍是巨大瓶颈：绝大多数有前景的探针仍停留在临床前或早期（I/II期）临床阶段。从实验室到临床，需跨越药代动力学优化、毒性评估、生产标准化等多重障碍。未来突破在于“组合”与“智能”：未来的研究应聚焦于：a) 探针设计革新，如开发小型化、双特异性分子以提升穿透力与亲和力；b) 联合治疗策略，如探索放射增敏剂与核素治疗、化疗、免疫治疗的协同方案；c) 智能化技术赋能，利用人工智能预测最佳给药剂量，并基于患者的基因分型（如KRAS突变状态）定制个体化诊疗方案。综上所述，尽管前路挑战重重，但放射性核素靶向策略无疑为攻克胰腺癌这一“癌王”提供了极具希望的新武器。它不仅是影像技术的革新，更是治疗范式的演进。随着新型分子靶点探针的持续开发、多学科协作的深化以及临床转化步伐的加快，胰腺癌诊疗的精准化与个性化突破正逐渐从愿景走向现实。参考文献： [1] Stoop T F, et al. Pancreatic cancer. Lancet, 2025. [2] Siegel R L, et al. Cancer statistics, 2024. CA Cancer J Clin, 2024. [3] Hu Z I, O’Reilly E M. Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol, 2024. [4] Wagle N S, et al. Cancer treatment and survivorship statistics, 2025. CA Cancer J Clin, 2025. [5] Jhala N, et al. Molecular tests in pancreatic cancer. J Natl Compr Canc Netw, 2024. [6] Ying H, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev, 2025. [7] Hu S, et al. (18)F-FDG-PET/CT findings in pancreatic metastasis. Radiol Med, 2015. [8] Ferdinandus J, et al. Theranostics in oncology. Eur J Radiol, 2021. [9] Hu M, et al. Advances in preclinical research of theranostic radiopharmaceuticals. ACS Appl Mater Interfaces, 2025. [10] Bidkar A P, et al. Treatment of prostate cancer with CD46-targeted 225Ac alpha particle radioimmunotherapy. Clin Cancer Res, 2023. [11] Wang J, et al. Preliminary study on the ability of the machine learning models based on (18)F-FDG PET/CT... Eur J Radiol, 2024. [12] Carlson D M, et al. Baseline characteristics and use of pretherapeutic 18F-fluorodeoxyglucose-PET for pancreatic cancer. J Am Coll Surg, 2024. [13] Suh H, et al. Mucins in pancreatic cancer. Am J Cancer Res, 2017. [14] Hull A, et al. Development of [225Ac]Ac-DOTA-C595 as radioimmunotherapy of pancreatic cancer. EJNMMI Radiopharm Chem, 2023. [15] Picozzi V J, et al. (90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine. Eur J Cancer, 2015. [16] Liu D, et al. Mesothelin-associated anti-senescence through P53 in pancreatic ductal adenocarcinoma. Cancers (Basel), 2025. [17] Kobayashi K, et al. A novel PET imaging using 64Cu-labeled monoclonal antibody against mesothelin. J Immunol Res, 2015. [18] Lu Z, et al. Preclinical evaluation of 89Zr/177Lu-labeled amatuximab for theranostic application in PDAC. Int J Pharm, 2024. [19] Wang X, et al. Construction and preclinical evaluation of 211At labeled anti-mesothelin antibodies. J Radiat Res, 2020. [20] Hung Y H, et al. Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance. Am J Cancer Res, 2024. [21] Hodolic M, et al. Safety and tolerability of 68Ga-NT-20.3 in patients with PDAC. Eur J Nucl Med Mol Imaging, 2021. [22] Pabst K M, et al. Detection of tumour heterogeneity... on [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT. Eur J Nucl Med Mol Imaging, 2024. [23] Puik J R, et al. 18F-prostate-specific membrane antigen PET/CT imaging for potentially resectable pancreatic cancer. Cancer Imaging, 2025. [24] Aziz M H, et al. Overexpression of the adhesion signaling pathway is linked to short-term survival in PDAC. Pancreatology, 2024. [25] Tsang K Y, et al. Development and characterization of an anti-cancer monoclonal antibody for treatment of human carcinomas. Cancers (Basel), 2022. [26] Schoffelen R, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer. Br J Cancer, 2013. [27] Hitchen N, et al. Recent advances in therapeutic targeting of the KRAS pathway in cancer. Pharmacol Ther, 2025. [28] Suyal C, et al. Structure-activity relationships of KRAS-G12D inhibitors for pancreatic cancer. Drug Discov Today, 2025. [29] Zhang Z, et al. Development and preclinical evaluation of radiolabeled covalent G12C-specific inhibitors. Mol Pharm, 2021. [30] Chen M H, et al. Cancer cell-intrinsic PD-1. Biomed Pharmacother, 2023. [31] Daunke T, et al. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of PDAC. Front Immunol, 2023. [32] van de Donk P P, et al. Molecular imaging to support cancer immunotherapy. J Immunother Cancer, 2022. [33] Burvenich I J G, et al. Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a. Theranostics, 2018. [34] Luo G P, et al. Roles of CA19-9 in pancreatic cancer. Biochim Biophys Acta Rev Cancer, 2021. [35] Poty S, et al. 89Zr-PET imaging of DNA double-strand breaks... in a mouse model of PDAC. Theranostics, 2020. [36] Zhu J, et al. In vivo PET imaging of EGFR expression: an overview of radiolabeled EGFR TKIs. Curr Top Med Chem, 2022. [37] Homedan A, et al. Protein-based radiopharmaceuticals that target fibroblast activation protein alpha. EJNMMI Radiopharm Chem, 2025. [38] Ganguly T, et al. Preclinical evaluation of 68Ga- and 177Lu-labeled integrin αvβ6-targeting radiotheranostic peptides. J Nucl Med, 2023. [39] Sachindra S, et al. SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-Integrin αvβ6 cystine knot peptide. Front Oncol, 2021. [40] Hu D Y, et al. Stromal fibronectin expression in patients with resected PDAC. World J Surg Oncol, 2019. [41] Jailkhani N, et al. Noninvasive imaging of tumor progression, metastasis, and fibrosis using a nanobody targeting the extracellular matrix. Proc Natl Acad Sci USA, 2019. [42] 黄敏. 靶向肿瘤代谢的新药研发：挑战与机遇. 药学进展, 2024. [43] 李顺尧, 等. 靶向肿瘤代谢酶小分子药物研究进展. 药学进展, 2024.

100 项与 90Y Clivatuzumab Tetraxetan 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	90Y Clivatuzumab Tetraxetan	-	DB15368

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性胰腺癌	临床3期	美国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	奥地利	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	比利时	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	加拿大	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	法国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	以色列	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	波兰	Gilead Sciences, Inc.	2013-12-01
转移性胰腺癌	临床3期	西班牙	Gilead Sciences, Inc.	2013-12-01
转移性胰腺腺癌	临床3期	美国	Gilead Sciences, Inc.	2013-12-01
转移性胰腺腺癌	临床3期	奥地利	Gilead Sciences, Inc.	2013-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01956812 (GlobeNewswire) 人工标引	临床3期	胰腺癌	-	Gemcitabine+yttrium-90-labeled (90Y) clivatuzumab tetraxetan	壓網夢襯廠鬱壓簾願網(鏇衊鏇窪鬱簾積壓鏇遞) = the treatment arm of 90Y-clivatuzumab tetraxetan combined with low-dose gemcitabine and best supportive care did not demonstrate a sufficient improvement in OS as compared to placebo plus low-dose gemcitabine and best supportive care. 鹽鏇襯鑰積選製觸淵遞 (壓膚鬱積蓋廠積網艱積 )	不佳	2016-03-14
				Gemcitabine+Placebo
NCT01510561 (Pubmed \| Eur J Cancer)	临床1期	转移性胰腺癌	53	(90)Y-clivatuzumab tetraxetan + gemcitabine	選夢艱鏇糧鏇廠構觸憲(製鬱築鹹醖繭簾蓋艱築) = 鑰廠窪蓋觸觸鑰觸顧衊獵壓鹹鬱構艱夢範觸遞 (鑰構淵淵膚構艱襯夢網 )	-	2015-09-01
				(90)Y-clivatuzumab tetraxetan alone	選夢艱鏇糧鏇廠構觸憲(製鬱築鹹醖繭簾蓋艱築) = 選簾構淵廠衊顧壓觸齋獵壓鹹鬱構艱夢範觸遞 (鑰構淵淵膚構艱襯夢網 )
NCT01510561 (ASCO2014)	临床1期	转移性胰腺癌	58	Arm A (GEM + <sup>90</sup>Y-clivatuzumab tetraxetan)	鏇糧廠壓鹹餘顧鏇選積(積廠選鹽顧憲鹹廠憲觸) = 糧鏇繭積觸構餘網艱襯顧壓顧衊網餘鏇膚鏇築 (築築鹹範衊襯鑰範鑰窪 )	-	2014-05-20
				Arm B (<sup>90</sup>Y-clivatuzumab tetraxetan alone)	鏇糧廠壓鹹餘顧鏇選積(積廠選鹽顧憲鹹廠憲觸) = 艱觸衊齋選餘蓋憲構憲顧壓顧衊網餘鏇膚鏇築 (築築鹹範衊襯鑰範鑰窪 )
ASCO_GI2012	临床1/2期	胰腺癌一线	100	90Y-hPAM4	鏇夢遞夢選壓範醖膚廠(蓋膚觸鹹鹹遞齋顧鏇製) = 願鹽淵窪襯獵鹹鬱廠獵獵糧衊鏇範醖醖壓鑰遞 (壓夢齋艱衊窪膚夢鏇鑰 )	-	2012-02-01
ASCO_GI2011	临床1/2期	胰腺癌	42	Clivatuzumab tetraxetan	積鬱鬱膚壓積製網衊範(餘膚鬱顧艱願獵壓鬱餘) = improved 繭憲艱鏇網醖構網獵夢 (淵製艱壓範築衊獵鬱蓋 )	-	2011-02-01
				Gemcitabine
ASCO2010	临床1/2期	胰腺癌	-	Clivatuzumab tetraxetan	窪艱獵膚築觸製觸鏇鬱(餘鑰積衊衊廠簾蓋衊壓) = 觸鏇膚壓淵淵簾繭繭鏇鏇築遞構鑰鏇窪壓夢鹽 (壓鏇糧襯艱鑰鏇壓選網 ) 更多	-	2010-05-20